Partial omission of bleomycin for early‐stage Hodgkin lymphoma patients treated with combined modality therapy: Does incomplete ABVD lead to inferior outcomes?

Classical Hodgkin lymphoma (HL) patients achieve excellent outcomes; therefore, treatment de‐escalation strategies to spare toxicity have been prioritized. In a large randomized trial of early‐stage HL patients, omission of chemotherapeutic agents including bleomycin from the standard ABVD (doxorubi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:EJHaem
Main Authors: Gunther, Jillian R., Pinnix, Chelsea C., Glober, Gordon R., Christopherson, Kaitlin M., Fang, Penny, Lee, Hun Ju, Ahmed, Sairah, Steiner, Raphael E., Nair, Ranjit, Strati, Paolo, Neelapu, Sattva S., Nastoupil, Loretta J., Dabaja, Bouthaina S.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Short Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7455016/
https://ncbi.nlm.nih.gov/pubmed/32864660
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jha2.1
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados